Piper Sandler Boosts Hims & Hers Health (NYSE:HIMS) Price Target to $13.00

Hims & Hers Health (NYSE:HIMS) had its target price raised by Piper Sandler from $11.00 to $13.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock.

HIMS has been the topic of a number of other research reports. Jefferies Financial Group restated a hold rating and set a $15.00 target price (down previously from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Truist Financial boosted their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a hold rating in a report on Tuesday, February 27th. Citigroup increased their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a buy rating in a report on Tuesday, February 27th. TheStreet raised shares of Hims & Hers Health from a d rating to a c rating in a report on Monday, March 4th. Finally, Guggenheim raised their price objective on Hims & Hers Health from $15.00 to $17.00 and gave the stock a buy rating in a research note on Tuesday, February 27th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of Moderate Buy and a consensus target price of $15.07.

Hims & Hers Health Trading Up 6.1 %

Shares of NYSE HIMS opened at $12.36 on Tuesday. The firm has a market capitalization of $2.65 billion, a PE ratio of -112.36 and a beta of 0.97. The firm’s 50-day moving average is $14.04 and its 200-day moving average is $10.35. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.05) EPS. As a group, equities research analysts anticipate that Hims & Hers Health will post 0.11 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other news, CEO Andrew Dudum sold 50,361 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Hims & Hers Health news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 50,361 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $16.34, for a total transaction of $822,898.74. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 736,191 shares of company stock valued at $9,733,700. Corporate insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in Hims & Hers Health in the 3rd quarter valued at $280,000. Bank of New York Mellon Corp raised its position in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after purchasing an additional 58,288 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Hims & Hers Health by 354.2% during the 3rd quarter. Mackenzie Financial Corp now owns 51,243 shares of the company’s stock worth $318,000 after buying an additional 39,962 shares during the last quarter. Strs Ohio boosted its holdings in shares of Hims & Hers Health by 33.0% during the 3rd quarter. Strs Ohio now owns 102,000 shares of the company’s stock worth $641,000 after buying an additional 25,300 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in Hims & Hers Health by 7.4% in the 3rd quarter. Teacher Retirement System of Texas now owns 72,253 shares of the company’s stock valued at $454,000 after buying an additional 4,954 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.